Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Kidney problems news

Show

From To
People with HIV/HCV co-infection at increased risk of kidney disease and bone disorders

Hepatitis C virus (HCV) infection in people with HIV co-infection is associated with an increased risk of liver disease and liver-related death and also several important non-liver related

Published
02 January 2017
By
Michael Carter
African Americans taking ART have high incidence of illness associated with risk of cardiovascular disease

Black HIV-positive men and women receiving antiretroviral therapy (ART) have especially high rates of health problems that can increase the long-term risk of cardiovascular disease, investigators from the

Published
20 December 2016
By
Michael Carter
Co-morbidities are common and rising among people with HIV in the US

People living with HIV are increasingly experiencing a range of non-AIDS-related co-morbidities as the population ages, including cardiovascular disease, kidney impairment and bone loss leading to fractures,

Published
19 December 2016
By
Liz Highleyman
Tenofovir alafenamide works well and improves kidney and bone markers in older people living with HIV

A co-formulation of tenofovir alafenamide (TAF) plus emtricitabine, used with a third antiretroviral drug, maintained viral suppression as well as tenofovir disoproxil fumarate (TDF) plus emtricitabine in older

Published
10 November 2016
By
Liz Highleyman
French study reveals the growing complexity of medical needs as people with HIV age

The complexity of the needs of people living with HIV will continue to increase as the population ages, and clinicians need to go beyond thinking about co-morbidities

Published
25 October 2016
By
Keith Alcorn
Less than 100% adherence to HIV therapy, even with viral suppression, can lead to more inflammation and immune activation

Research involving men taking antiretroviral therapy, all with an undetectable viral load, has shown that imperfect adherence to therapy is associated with higher levels of key markers of

Published
12 October 2016
By
Michael Carter
Ask A Pharmacist: With a new tenofovir, should you switch to Descovy, Genvoya or Odefsey?

I’ve heard more than a few patients ask, what should I do? If I’m already taking Complera, Stribild or Truvada, should I switch to the newer drug formulation with tenofovir alafenamide (TAF)?

Published
20 September 2016
From
BETA blog
Managing non-communicable diseases among people living with HIV

Non-communicable diseases (NCDs) – including cardiovascular diseases, diabetes, cancers, and other illnesses – will represent a significant challenge for HIV care in low- and middle-income countries as

Published
13 September 2016
By
Theo Smart
Poor kidney function associated with increased cardiovascular risk for people with HIV

Renal impairment is associated with an increased risk of cardiovascular disease (CVD) in HIV-positive individuals, according to data from a large observational cohort study published in the online

Published
18 August 2016
By
Michael Carter
Bone loss partially recovers after stopping PrEP, twice-yearly kidney monitoring is enough for most

Young adults taking Truvada for pre-exposure prophylaxis (PrEP) experienced a modest decrease in bone mineral density early on, but this stabilised after a year and those who stopped

Published
26 July 2016
By
Liz Highleyman
← First12345...12Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.